Gonzalo Fernández-Hinojal

5PUBLICATIONS
62CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Jun 01, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.

Zofia Piotrowska, Antonio Passaro, Danny Nguyen

|Jun 27, 2023
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.

Ana Bocanegra, Gonzalo Fernández-Hinojal, Daniel Ajona

|Dec 31, 2021
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.

Carolyn J Edwards, Angelica Sette, Carl Cox

Pageof 1